TriSalus Life Sciences: Stevens sells 316 shares

The Chief Regulatory Officer's transaction was tied to tax withholding when previously granted restricted stock units vested, not a discretionary sale.

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. Chief Regulatory Officer Jennifer Stevens reported selling 316 common shares at $4.39 per share on October 5, 2026. The shares were sold to satisfy tax withholding obligations connected with vesting of previously granted restricted stock units; the transaction does not represent a discretionary sale. Her directly held position after the transaction was 123,794 shares. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 316 shares

Net Sell 1 txn

Insider Stevens Jennifer

Role Chief Regulatory Officer

Sold 316 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	316	$4.39	$1K

Holdings After Transaction: Common Stock — 123,794 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This transaction does not represent a discretionary sale by the Reporting Person.

Key Figures

Shares sold: 316 shares Sale price: $4.39 per share Direct shares held after transaction: 123,794 shares

3 metrics

Shares sold 316 shares October 5, 2026

Sale price $4.39 per share October 5, 2026

Direct shares held after transaction 123,794 shares Following the October 5, 2026 transaction

Key Terms

restricted stock units, tax withholding obligations, discretionary sale

3 terms

restricted stock units financial

"vesting of restricted stock units previously granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold to satisfy tax withholding obligations"

discretionary sale financial

"does not represent a discretionary sale by the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TLSI shares did the Chief Regulatory Officer sell?

Jennifer Stevens, TriSalus Life Sciences' Chief Regulatory Officer, reported selling 316 common shares at $4.39 per share on October 5, 2026. The shares were sold to satisfy tax withholding obligations tied to vesting of previously granted restricted stock units; the transaction does not represent a discretionary sale. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:03 PM Accepted by SEC EDGAR 10/07/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stevens Jennifer

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		S		316(1)	D	$4.39	123,794	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This transaction does not represent a discretionary sale by the Reporting Person.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)